

Date: 10th November, 2023

To,
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai – 400 001

Dear Sir / Madam,

Subject: Submission of Unaudited Financial Results for the Half Year ended on 30th September, 2023 along with Limited Review Report

Ref: Security Id: EVOQ / Code: 543500

In reference to captioned subject and pursuant to Regulation 33(3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are hereby submitting the Unaudited Financial Results for the half year ended on 30th September, 2023 along with Limited Review Report.

Kindly take the same on your record and oblige us.

Thanking You.

For, Evoq Remedies Limited



Bhumishth Patel
Managing Director
DIN: 02516641

EVOQ REMEDIES LIMITED. CIN:L24230GJ2010PLC059692

A-1106, EMPIRE BUSINESS HUB, SCIENCE CITY ROAD, AHMEDABAD

UNAUDITED FINANCIAL RESULTS FOR THE HALF YEAR ENDED 30TH SEPTEMBER, 2023

Particulars	6 Months Ended			Year Ended
	30.09.2023 (Unaudited)	31.03.2023 (Audited)	30.09.2022 (Unaudited)	For the Period Ended 31st March 2023
	Rs. (In Lacs)	Rs. (In Lacs)	Rs. (In Lacs)	Rs. (In Lacs)
I. Revenue from Operations	390.26	459.93	1579.05	2038.98
II Other Income	-	602	-	602.27
Total Revenue (I + II)	390.26	1,062.20	1,579.05	2641.25
III. Expenses:				
Purchases of material	182.61	455.91	1601.66	2057.57
Changes in Inventories	47.30	(32.97)	(91.80)	(124.77)
Employee Benefits Expenses	5.87	11.47	8.92	20.39
Finance Costs	-	0.12	0.01	0.13
Depreciation and Amortization expense	0.45	0	-	0.39
Other Expenses	147.10	429.42	29.67	459.09
Total Expenses	383.33	864.34	1,548.46	2,412.80
IV. Profit before exceptional and extraordinary items and tax (III-IV)	6.93	197.86	30.59	228.45
V. Exceptional Items Prior Period Expenses				
VI. Profit Before Extraordinary Items and Tax (V - VI)	6.93	197.86	30.59	228.45
VIII. Extraordinary Items				
IX. Profit before tax (VII- VIII)	6.93	197.86	30.59	228.45
X Tax expense:				
(1) Current tax	1.93	66.53	0	66.53
(2) Deferred tax				
XI Profit (Loss) for the period from continuing operations (VI- VIII)	5.00	131.33	30.59	161.92
XII Profit/(loss) from discontinuing operations	-	-	-	-
XIII Tax expense of discontinuing operations	-	-	-	-
XIV Profit/(loss) from Discontinuing operations (after tax) (XII- XIII)	-	-	-	-
XV Profit (Loss) for the period (XI + XIV)	5.00	131.33	30.59	161.92
XVI BALANCE BROUGHT FROM PREVIOUS YEAR				
XVII BALANCE CARRIED TO BALANCE SHEET	5.00	131.33	30.59	161.92
XVIII Details of equity Share Capital				
Paid Up Equity Share Capital	1360	1360	1360	1360
Face Value of equity share Capital	10	10	10	10
XVIII Earnings per equity share:				
(1) Basic	0.04	0.97	0.02	1.19
(2) Diluted	0.04	0.97	0.02	1.19

Notes :

Notes:-

- The above Unaudited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meeting held on November 10, 2023
- IND AS 108 Relating to Segment wise reporting is not applicable as the Company operates in only One Primary segment i.e Pharmaceutical Trading.
- There are no investor complaints received/pending as on September 30, 2023
- Previous year's/ period figures have been regrouped/ reclassified/ restated, wherever necessary to confirm to classification of current year/period.

For, Evoq Remedies Limited

BHUMISHTH PATEL
Managing Director
DIN : 02516641
PLACE:AHMEDABAD
DATE: 10/11/2023

EVOQ REMEDIES LIMITED. CIN:L24230GJ2010PLC059692

A-1106, EMPIRE BUSINESS HUB, SCIENCE CITY ROAD, AHMEDABAD

UNAUDITED BALANCE SHEET AS AT 30TH SEPTEMBER 2023

Particulars	Year Ended	
	30.09.2023 (Unaudited)	31.03.2023 (Audited)
	Rs. (In Lacs)	Rs. (In Lacs)
I. EQUITY AND LIABILITIES		
1 Shareholders Funds		
(a) Share Capital	1,360.00	1,360.00
(b) Reserves and Surplus	1,123.55	1,118.55
(c) Money Received Against Share Warrents	-	-
Total Shareholders Funds	2,483.55	2,478.55
3 Non-Current Liabilities		
(a) Long-Term Borrowings	-	-
(b) Deferred Tax Liabilities (Net)	-	-
(c) Other Long Term Liabilities	-	-
(d) Long-Term Provisions	-	-
Total Non Current Liabilites	-	-
4 Current Liabilities		
(a) Short-Term Borrowings	127.59	957.62
(b) Trade Payables		
i) Total Outstanding dues of micro enterprise and small	218.28	(16.28)
ii) Total Outstanding dues of creditors other than micro		
enterprise and small enterprise	121.97	(37.38)
(c) Other Current Liabilities	40.63	20.67
(d) Short-Term Provisions	88.60	86.67
Total Current Liabilities	597.07	1,011.30
TOTAL >>>>	3,080.62	3,489.85
II. ASSETS		
Non-Current Assets		
1 (a) Fixed Assets		
(i) Tangible Assets	1.79	0.93
(ii) Intangible Assets	-	-
(iii) Capital Work-In-Progress	-	-
(iv) Intangible Assets under Development	-	-
(b) Non-Current Investments	-	-
(c) Deferred Tax Assets (Net)	-	-
(d) Long-Term Loans and Advances	-	-
(e) Other Non-Current Assets	-	-
Total Non Current Assets	1.79	0.93
2 Current Assets		
(a) Current Investments	-	-
(b) Inventories	155.91	203.21
(c) Trade Receivables	1,113.75	1,721.55
(d) Cash and Cash Equivalents	5.67	15.36
(e) Short-Term Loans and Advances	1,053.57	786.92
(f) Other Current Assets	749.93	761.88
Total Current Assets	3,078.83	3,488.92
TOTAL >>>>	3,080.62	3,489.85
See accompanying notes forming part of the Financial Statements		

As per our report of even date

For, Evoq Remedies Limited

BHUMISHTH PATEL
Managing Director
DIN : 02516641
PLACE:AHMEDABAD
DATE: 10/11/2023

CASH FLOW STATEMENT FOR THE PERIOD ENDED 30TH SEPTEMBER 2023

Rs. (In Lacs)

<u>Particulars</u>	For the Period Ended 30th September 2023	For the Year Ended 31st March,2023
Cash flows from operating activities		
Profit before taxation	6.93	228.45
Adjustments for:		
Depreciation	0.45	0.39
Investment income	-	-
Deferred tax Liability	-	-
Interest expense	-	0.13
Profit / (Loss) on the sale of property, plant & equipment	-	-
Working capital changes:		
(Increase) / Decrease in trade and other receivables	607.80	818.19
(Increase) / Decrease in inventories	47.30	(124.77)
(Increase) / Decrease in Short Term Loan & Advance	(266.65)	(413.41)
(Increase) / Decrease in Other Current Assets	11.95	(729.86)
Increase / (Decrease) in Trade payables	393.91	(174.52)
Increase / (Decrease) in Short term Provisions	1.93	49.96
Increase / (Decrease) in Other Current Liabilities	19.96	(22.47)
Cash generated from operations	823.58	(367.91)
Interest paid	-	(0.13)
Income taxes paid	(1.93)	(66.53)
Dividends paid	-	-
Net cash from operating activities	821.65	(434.57)
Cash flows from investing activities		
Business acquisitions, net of cash acquired	-	-
Purchase of property, plant and equipment	(1.31)	(1.31)
Proceeds from sale of equipment	-	-
Acquisition of portfolio investments	-	-
Investment income	-	-
Net cash used in investing activities	(1.31)	(1.31)
Cash flows from financing activities		
Proceeds from issue of share capital	-	-
Proceeds from long-term borrowings	-	-
Proceeds from Short-term borrowings	(830.03)	141.82
Payment of Share Application Money	-	-
Share Capital Issue With Security Premium	-	-
Net cash used in financing activities	(830.03)	141.82
Net increase in cash and cash equivalents	(9.69)	(294.06)
Cash and cash equivalents at beginning of period	15.36	309.42
Cash and cash equivalents at end of period	5.67	15.36

As per our report of even date

For, Evoq Remedies Limited

BHUMISHTH PATEL
Managing Director
DIN : 02516641

PLACE:AHMEDABAD
DATE: 10/11/2023

Manoj Acharya & Associates

CHARTERED ACCOUNTANTS

Telephone Office : 079-26589713

Mobile : +91 - 9825633346

219, Ashirwad Market,

Kalupur, AHMEDABAD - 380002



E-mail :manojca1991@gmail.com

LIMITED REVIEW REPORT OF EVOQ REMEDIES LIMITED

Review Report to

To,

The Board of Directors,

EVOQ REMEDIES LIMITED

CIN : L24230GJ2010PLC059692

AHMEDABAD

We have reviewed the accompanying statement of unaudited financial results of **EVOQ REMEDIES LIMITED (CIN: L24230GJ2010PLC059692)** for the half year ended **30th September, 2023**. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For MANOJ ACHARYA & ASSOCIATES,

Chartered Accountants

FRN: 114984W

Manoj Acharya

CA MANOJ ACHARYA

Partner

M. No. 045714

UDIN: 23045714BGQULQ4971



Place: Ahmedabad

Date: 10/11/2023